tldrdailynews.com logo
Tag

Orforglipron

All articles tagged with #orforglipron

New Oral GLP-1 Pill Shifts the Weight-Loss Race Against Ozempic
health16 days ago

New Oral GLP-1 Pill Shifts the Weight-Loss Race Against Ozempic

A 52-week phase-3 trial in 1,698 adults with type 2 diabetes across six countries found orforglipron, a daily oral small-molecule GLP-1 drug, reduced HbA1c more and produced greater weight loss than oral semaglutide (1.71–1.91% vs 1.47% HbA1c and 6.1–8.2 kg vs 5.3 kg), but caused more gastrointestinal side effects and higher discontinuation (~10% vs 4–5%). It’s cheaper to manufacture and doesn’t require refrigeration, giving it logistical advantages, though long-term comparisons with injectable GLP-1 therapies and obesity trials without diabetes are still underway.

via ScienceAlert|
#diabetes#glp-1#health
Lilly’s Orforglipron Edges Novo’s GLP-1 Pill in Major Diabetes Trial
business1 month ago

Lilly’s Orforglipron Edges Novo’s GLP-1 Pill in Major Diabetes Trial

In a year-long, head-to-head trial with 1,698 diabetes patients, Eli Lilly’s oral GLP-1 pill orforglipron outperformed Novo Nordisk’s Rybelsus on blood sugar control and weight loss (roughly 15–20 lbs vs 8–11 lbs), with better cardiovascular markers. Higher doses brought more GI side effects (about 10% dropout). The pill can be taken anytime, doesn’t require refrigeration, and Lilly aims for U.S. availability by mid-2026 at about $145–$399 out of pocket.

via Business Insider|
#business#diabetes#glp-1
Medicare tailwinds could accelerate Lilly’s obesity-pill rollout
business2 months ago

Medicare tailwinds could accelerate Lilly’s obesity-pill rollout

Eli Lilly CEO Dave Ricks says Medicare coverage of obesity treatments later this year could be a major catalyst for the launch of orforglipron, with a full rollout planned in Q2 and price reductions expected in the second half under Trump-era deals; the move could expand access to 20–30 million beneficiaries and follows strong early demand for competitor Wegovy, a GLP-1 obesity pill.

via CNBC|
#business#eli-lilly#glp-1
Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss
health2 months ago

Next-Gen GLP-1 Drugs Aim to Overtake Ozempic in Weight Loss

Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.

via Gizmodo|
#cagrisema#glp-1-therapy#health
Eli Lilly's forforglipron Shows Promising Results in Weight Loss and Obesity Treatment
health7 months ago

Eli Lilly's forforglipron Shows Promising Results in Weight Loss and Obesity Treatment

Eli Lilly's experimental oral GLP-1 pill, orforglipron, helped overweight adults with type 2 diabetes lose an average of 10.5% of their body weight in a late-stage trial, with significant improvements in blood sugar levels, positioning it as a promising alternative to injectable obesity drugs and potentially paving the way for regulatory approval and market launch next year.

via Reuters|
#glp-1-pill#health#lilly
health8 months ago

Eli Lilly's New Weight-Loss Pill Shows Promising Results in Human Trials

Eli Lilly's new weight loss pill, orforglipron, shows promising trial results with an average weight loss of 12.4% over 72 weeks, nearing the effectiveness of existing injections like Mounjaro and Wegovy. The pill could be easier and cheaper to produce and take, potentially making weight loss treatment more accessible through the NHS, although its efficacy is slightly lower than injectable options. Regulatory approval is anticipated soon, which could mark a significant advancement in obesity management.

via LADbible|
#health#mounjaro#nhs
Eli Lilly Pill Shows Significant Weight Loss in Trial
health8 months ago

Eli Lilly Pill Shows Significant Weight Loss in Trial

Eli Lilly's new pill, orforglipron, has shown promising results in causing significant weight loss in adults with obesity, with an average loss of 27.3 pounds at the highest dose, and the company plans to seek FDA approval by the end of the year. The pill offers a potentially more accessible alternative to injectable weight-loss drugs, with manufacturing advantages, though its full efficacy and safety profile are yet to be fully disclosed.

via The New York Times|
#eli-lilly#fda-approval#health